网站首页
概要
Human primary B cells derived from peripheral blood (PB) are isolated from mononuclear cells (MNCs) using the negative immunomagnetic selection technique. Cells are untouched and ready for downstream applications. PB was collected using acid-citrate-dextrose solution A (ACDA) as the anticoagulant.
Cells were obtained using Institutional Review Board (IRB)-approved consent forms and protocols.
Certain products are only available in select territories. Please contact your local Sales representative or Product & Scientific Support at techsupport@stemcell.com for further information.
Browse our Frequently Asked Questions (FAQs) on Primary Cells.
Cells were obtained using Institutional Review Board (IRB)-approved consent forms and protocols.
Certain products are only available in select territories. Please contact your local Sales representative or Product & Scientific Support at techsupport@stemcell.com for further information.
Browse our Frequently Asked Questions (FAQs) on Primary Cells.
技术资料
| Document Type | 产品名称 | Catalog # | Lot # | 语言 |
|---|---|---|---|---|
| Product Information Sheet | Human Peripheral Blood B Cells, Frozen | 70023, 70023.1 | All | English |
数据及文献
Data
Figure 1. Cryopreserved B Cells Show High Viability and Produce IgG Antibodies Upon Stimulation
(A) B Cells (Catalog #70023) cryopreserved in CryoStor® CS10 (Catalog #07930) show high viability upon thawing (average = 96.3 ± 0.6 %, n = 6). (B) B cells were cultured for 1 week in RPMI 1640 Medium (Catalog #36750) with 10% FBS, 2mM L-Glutamine (Catalog #07100), 10mM HEPES (Catalog #07200) and 55 µM β-mercaptoethanol and either left unstimulated (control) or stimulated with CD40 in the presence of IL-21 (activated). Activated B cells produce significantly more IgG antibodies compared to unstimulated controls as measured by ELISA.
Publications (1)
Journal of medicinal chemistry 2014 MAY
Discovery of GS-9973, a selective and orally efficacious inhibitor of spleen tyrosine kinase.
Abstract
Abstract
Spleen tyrosine kinase (Syk) is an attractive drug target in autoimmune, inflammatory, and oncology disease indications. The most advanced Syk inhibitor, R406, 1 (or its prodrug form fostamatinib, 2), has shown efficacy in multiple therapeutic indications, but its clinical progress has been hampered by dose-limiting adverse effects that have been attributed, at least in part, to the off-target activities of 1. It is expected that a more selective Syk inhibitor would provide a greater therapeutic window. Herein we report the discovery and optimization of a novel series of imidazo[1,2-a]pyrazine Syk inhibitors. This work culminated in the identification of GS-9973, 68, a highly selective and orally efficacious Syk inhibitor which is currently undergoing clinical evaluation for autoimmune and oncology indications.
